^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma

Excerpt:
Confirming the specificity of the rescue, SRCT341I cells also showed increased resistance to saracatinib and bosutinib, but not ponatinib, which is designed to overcome this gatekeeper mutation.
DOI:
10.1158/2159-8290.CD-15-1442